Compare MNRO & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNRO | DNA |
|---|---|---|
| Founded | 1957 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 678.1M | 607.1M |
| IPO Year | 1994 | N/A |
| Metric | MNRO | DNA |
|---|---|---|
| Price | $22.21 | $9.38 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $17.67 | $10.50 |
| AVG Volume (30 Days) | 843.0K | ★ 973.2K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $1,195,334,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.59 | $3.07 |
| P/E Ratio | $86.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.20 | $5.00 |
| 52 Week High | $23.91 | $17.58 |
| Indicator | MNRO | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.92 | 52.27 |
| Support Level | $16.19 | $8.19 |
| Resistance Level | $23.91 | $10.16 |
| Average True Range (ATR) | 0.82 | 0.77 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 62.31 | 65.28 |
Monro Inc is an operator of retail tire and automotive repair stores in the United States. The company offers replacement tires and tire related services, automotive undercar repair services, and a broad range of routine maintenance services, on passenger cars, light trucks, and vans. It also provides other products and services for brakes; mufflers and exhaust systems; and steering, drive train, suspension, and wheel alignment.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.